Historical Press Releases

2013

Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration

Princeton, NJ and Germantown, MD – May 1, 2013 – Soligenix, Inc. (OTCQB: SNGX), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and...

Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments

Princeton, NJ – May 3, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases...

Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn’s Disease

Princeton, NJ – May 14, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory...

Soligenix Announces Issuance of US Patent for its ThermoVax™ Technology

Princeton, NJ – May 22, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory...

FDA Grants Soligenix “Fast Track” Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer

Princeton, NJ – June 3, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the...

Soligenix Announces Pricing of Public Offering of Common Stock and Warrants

Princeton, NJ – June 21, 2013 – Soligenix, Inc. (OTCQB: SNGX) (“Soligenix” or the “Company”), a clinical stage biopharmaceutical company focused on developing products to treat...

Soligenix Closes $7.1 Million Public Offering

Princeton, NJ – June 26, 2013 – Soligenix, Inc. (OTCQB: SNGX) (“Soligenix” or the “Company”), a clinical stage biopharmaceutical company focused on developing products to treat...

Soligenix Completes Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn’s Disease

Princeton, NJ – June 28, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory...

Soligenix Announces Commercial Collaboration with SciClone Pharmaceuticals in China for SGX942 in the Treatment of Oral Mucositis

Princeton, NJ – July 8, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory...

Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments

Princeton, NJ – August 12, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory...

Show per page